China has moved to restrict foreign acquisitions of biotech companies, tightening the rules for cross-border ownership in a sector that has increasingly attracted strategic interest from international players. The development is part of a broader effort to bring biotechnology investment and control under more direct national oversight. For global drugmakers and investors, the shift can change deal timelines, reduce optionality on regulatory approvals, and add new diligence requirements around governance, technology transfer, and data-handling commitments. The policy direction will be closely watched by both acquirers and targets as it affects the near-term feasibility of transactions involving platform technology, clinical-stage assets, and domestic supply chains. Market participants are expected to recalibrate deal structures and consider more joint-venture or licensing pathways where equity transfers face increased friction.